Cargando…
Assessment of increasing intravenous adenosine dose in fractional flow reserve
BACKGROUND: Effects of increased adenosine dose in the assessment of fractional flow reserve (FFR) were studied in relation to FFR results, hemodynamic effects and patient discomfort. FFR require maximal hyperemia mediated by adenosine. Standard dose is 140 μg/kg/min administrated intravenously. Hig...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5310024/ https://www.ncbi.nlm.nih.gov/pubmed/28196527 http://dx.doi.org/10.1186/s12872-016-0463-4 |
_version_ | 1782507807137857536 |
---|---|
author | Sparv, David Götberg, Matthias Harnek, Jan Persson, Tobias Madsen Hardig, Bjarne Erlinge, David |
author_facet | Sparv, David Götberg, Matthias Harnek, Jan Persson, Tobias Madsen Hardig, Bjarne Erlinge, David |
author_sort | Sparv, David |
collection | PubMed |
description | BACKGROUND: Effects of increased adenosine dose in the assessment of fractional flow reserve (FFR) were studied in relation to FFR results, hemodynamic effects and patient discomfort. FFR require maximal hyperemia mediated by adenosine. Standard dose is 140 μg/kg/min administrated intravenously. Higher doses are commonly used in clinical practice, but an extensive comparison between standard intravenous dose and a high dose (220 μg/kg/min) has previously not been performed. METHODS: Seventy-five patients undergoing FFR received standard dose adenosine, followed by high dose adenosine. FFR, mean arterial pressure (MAP) and heart rate (HR) were analyzed. Patient discomfort measured by Visual Analogue Scale (VAS) was assessed. RESULTS: No significant difference was found between the doses in FFR value (0.85 [0.79–0.90] vs 0.85 [0.79–0.89], p = 0.24). The two doses correlated well irrespective of lesion severity (r = 0.86, slope = 0.89, p = <0.001). There were no differences in MAP or HR. Patient discomfort was more pronounced using high dose adenosine (8.0 [5.0–9.0]) versus standard dose (5.0 [2.0–7.0]), p = <0.001. CONCLUSIONS: Increased dose adenosine does not improve hyperemia and is associated with increased patient discomfort. Our findings do not support the use of high dose adenosine. TRIAL REGISTRATION: Retrospective Trial registration: Current Controlled Trials ISRCTN14618196. Registered 15 December 2016. |
format | Online Article Text |
id | pubmed-5310024 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-53100242017-03-13 Assessment of increasing intravenous adenosine dose in fractional flow reserve Sparv, David Götberg, Matthias Harnek, Jan Persson, Tobias Madsen Hardig, Bjarne Erlinge, David BMC Cardiovasc Disord Research Article BACKGROUND: Effects of increased adenosine dose in the assessment of fractional flow reserve (FFR) were studied in relation to FFR results, hemodynamic effects and patient discomfort. FFR require maximal hyperemia mediated by adenosine. Standard dose is 140 μg/kg/min administrated intravenously. Higher doses are commonly used in clinical practice, but an extensive comparison between standard intravenous dose and a high dose (220 μg/kg/min) has previously not been performed. METHODS: Seventy-five patients undergoing FFR received standard dose adenosine, followed by high dose adenosine. FFR, mean arterial pressure (MAP) and heart rate (HR) were analyzed. Patient discomfort measured by Visual Analogue Scale (VAS) was assessed. RESULTS: No significant difference was found between the doses in FFR value (0.85 [0.79–0.90] vs 0.85 [0.79–0.89], p = 0.24). The two doses correlated well irrespective of lesion severity (r = 0.86, slope = 0.89, p = <0.001). There were no differences in MAP or HR. Patient discomfort was more pronounced using high dose adenosine (8.0 [5.0–9.0]) versus standard dose (5.0 [2.0–7.0]), p = <0.001. CONCLUSIONS: Increased dose adenosine does not improve hyperemia and is associated with increased patient discomfort. Our findings do not support the use of high dose adenosine. TRIAL REGISTRATION: Retrospective Trial registration: Current Controlled Trials ISRCTN14618196. Registered 15 December 2016. BioMed Central 2017-02-14 /pmc/articles/PMC5310024/ /pubmed/28196527 http://dx.doi.org/10.1186/s12872-016-0463-4 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Sparv, David Götberg, Matthias Harnek, Jan Persson, Tobias Madsen Hardig, Bjarne Erlinge, David Assessment of increasing intravenous adenosine dose in fractional flow reserve |
title | Assessment of increasing intravenous adenosine dose in fractional flow reserve |
title_full | Assessment of increasing intravenous adenosine dose in fractional flow reserve |
title_fullStr | Assessment of increasing intravenous adenosine dose in fractional flow reserve |
title_full_unstemmed | Assessment of increasing intravenous adenosine dose in fractional flow reserve |
title_short | Assessment of increasing intravenous adenosine dose in fractional flow reserve |
title_sort | assessment of increasing intravenous adenosine dose in fractional flow reserve |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5310024/ https://www.ncbi.nlm.nih.gov/pubmed/28196527 http://dx.doi.org/10.1186/s12872-016-0463-4 |
work_keys_str_mv | AT sparvdavid assessmentofincreasingintravenousadenosinedoseinfractionalflowreserve AT gotbergmatthias assessmentofincreasingintravenousadenosinedoseinfractionalflowreserve AT harnekjan assessmentofincreasingintravenousadenosinedoseinfractionalflowreserve AT perssontobias assessmentofincreasingintravenousadenosinedoseinfractionalflowreserve AT madsenhardigbjarne assessmentofincreasingintravenousadenosinedoseinfractionalflowreserve AT erlingedavid assessmentofincreasingintravenousadenosinedoseinfractionalflowreserve |